1. Comparative Evaluation of Different Chitosan Species and Derivatives as Candidate Biomaterials for Oxygen-Loaded Nanodroplet Formulations to Treat Chronic Wounds.
- Author
-
Argenziano M, Bressan B, Luganini A, Finesso N, Genova T, Troia A, Giribaldi G, Banche G, Mandras N, Cuffini AM, Cavalli R, and Prato M
- Subjects
- Biocompatible Materials pharmacology, Cell Hypoxia drug effects, Cell Survival drug effects, HaCaT Cells, Humans, Keratinocytes drug effects, Keratinocytes pathology, Molecular Weight, Nanoparticles, Oxygen pharmacology, Particle Size, Wounds and Injuries pathology, Biocompatible Materials administration & dosage, Chitosan chemistry, Oxygen administration & dosage, Wounds and Injuries drug therapy
- Abstract
Persistent hypoxia is a main clinical feature of chronic wounds. Intriguingly, oxygen-loaded nanodroplets (OLNDs), filled with oxygen-solving 2H,3H-decafluoropentane and shelled with polysaccharides, have been proposed as a promising tool to counteract hypoxia by releasing a clinically relevant oxygen amount in a time-sustained manner. Here, four different types of chitosan (low or medium weight (LW or MW), glycol-(G-), and methylglycol-(MG-) chitosan) were compared as candidate biopolymers for shell manufacturing. The aim of the work was to design OLND formulations with optimized physico-chemical characteristics, efficacy in oxygen release, and biocompatibility. All OLND formulations displayed spherical morphology, cationic surfaces, ≤500 nm diameters (with LW chitosan-shelled OLNDs being the smallest), high stability, good oxygen encapsulation efficiency, and prolonged oxygen release kinetics. Upon cellular internalization, LW, MW, and G-chitosan-shelled nanodroplets did not significantly affect the viability, health, or metabolic activity of human keratinocytes (HaCaT cell line). On the contrary, MG-chitosan-shelled nanodroplets showed very poor biocompatibility. Combining the physico-chemical and the biological results obtained, LW chitosan emerges as the best candidate biopolymer for future OLND application as a skin device to treat chronic wounds.
- Published
- 2021
- Full Text
- View/download PDF